A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Status:
Completed
Trial end date:
2020-11-25
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to estimate overall response rate (ORR) of SHR-1210 combined
with capecitabine and oxaliplatin or with apatinib as first-line treatment in subjects with
locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.